Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2005

View Archived Issues

Data presented on the potential of KRP-203 in clinical transplantation

Minocycline accelerates the recovery of olfactory sensory neurons

mGluR5 antagonist MTEP demonstrates antiparkinsonian effects

Update on preclinical pharmacological profile of tanaproget

LGD-5552 exhibits potent antiinflammatory activity

TLR4 agonists trigger innate resistance in infectious challenge

Good results reported for the Cypher stent in complex CAD patients

Preliminary results on the efficacy of Tovaxin in multiple sclerosis

Promising phase I data on the effects and safety of BMS-188797 in solid malignancies

p38 MAP kinase: a target for pulmonary hypertension

Dual TACE/MMP inhibition is effective for arthritis

Revlimid NDA accepted for review

New license for use of paclitaxel in treatment of emphysema

Aegis Therapeutics enters into Intravail agreements

Meditech Pharmaceuticals to change name to Deli Solar

BioInvent and CAT sign license agreement

Pentoxifylline studied to stop progression of NASH

LCL-204 induces apoptosis in human prostate carcinoma cells

MorphoSys grants ImmunoGen access to HuCAL GOLD

Affitech grants license for Protein L

Boehringer Ingelheim and AbGenomics sign antibody agreement

Oxford BioMedica licenses LentiVector technology to Pfizer

Anatibant receives orphan drug designation for severe traumatic brain injury

Factive meets primary endpoint in phase III study of five-day CAP treatment

Ligand earns new milestone from GSK collaboration

Human embryonic stem cell-derived HSCs establish hematopoiesis in mice

Merck & Co. patents cover novel NR2B receptor antagonists

Recent Bayer patent describes new antiretroviral agents

New treatments for diabetes reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...